USDA claims to have discovered a "marketable" ASF vaccine

Published 2021년 10월 21일

Tridge summary

Researchers from the USDA have developed a vaccine against African swine fever (ASF) that has the potential to be commercially produced and maintained for vaccination efficacy. The vaccine can protect European and Asian pigs from the current Asian strain of the virus. The vaccine has shown immunity in a third of the animals after two weeks and full protection in all animals by the fourth week. The USDA is planning to commercialize the vaccine with Navetco, a Vietnamese national veterinary society, and is also evaluating other potential business partners for vaccine development. The USDA has developed and patented five experimental ASF vaccines and has entered into seven licenses with pharmaceutical companies for vaccine development.

Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

Researchers from the United States Department of Agriculture (USDA) claim to have succeeded in producing a vaccine against African swine fever (ASF) that has "the ability to be produced commercially, while maintaining its vaccination efficacy." This experimental vaccine can "effectively prevent and protect the offspring of European and Asian pigs against the strain currently circulating in Asia," USDA's Agricultural Research Service (ARS) said in a statement on September 30. The results and their work, published on September 28 in the journal "Transboundary and emerging diseases", show an appearance of immunity "in approximately a third of the animals the second week after the vaccine", then a "total protection in all the animals at the fourth week ”. This experimental vaccine can "effectively prevent and protect the offspring of European and Asian pigs against the strain currently circulating in Asia." American researchers have already developed a recombinant vaccine focused on ...

Source: Agropopular